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The applicability of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) in the clinic/industry is 
highly dependent on the development of efficient methods for worldwide shipment of these cells. Here, we 
evaluated the feasibility to cold store monolayers and aggregates of functional CMs obtained from different PSC 
lines using a fully defined clinical-compatible preservation formulation and investigated the time frame that 
hPSC-CMs could be subjected to hypothermic storage.  
 
We showed that two-dimensional (2D) monolayers of hPSC-CMs can be efficiently stored at 4°C for 3 days 
without compromising cell viability. However, cell viability decreased when the cold storage interval was 
extended to 7 days. We demonstrated that hPSC-CMs are more resistant to prolonged hypothermic storage-
induced cell injury in three-dimensional aggregates than in 2D monolayers, showing high cell recoveries (>70%) 
after 7 days of storage. Importantly, hPSC-CMs maintained their typical (ultra)structure, gene and protein 
expression profile, electrophysiological profiles, and drug responsiveness. 
 
This study provides important insights into the cold preservation of PSC-CMs that could be valuable in 
improving global commercial distribution of hPSC-CMs. 
 
 
 
 
 
